Humalog U-200 KwikPen Launched

Share this content:
Eli Lilly and Company announced launch of new Humalog U-200 KwikPen.
Eli Lilly and Company announced launch of new Humalog U-200 KwikPen.

Eli Lilly and Company announced the launch of Humalog 200 units/mL KwikPen (insulin lispro 200 units/mL [U-200]).

Humalog is a rapid-acting human insulin analog indicated to improve glycemic control in adults and children with type 1 and type 2 diabetes already taking mealtime insulin. 

Humalog U-200 KwikPen is a prefilled pen that holds twice as many units of insulin (600 units) as the U-100 formulation (300 units) in the same 3-mL cartridge volume. It does not require dose conversions and can be dialed in 1-unit increments to a maximum of 60 units per injection. This formulation reduces the number of pen changes per month.

Insulin lowers blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. It inhibits lipolysis and proteolysis, and enhances protein synthesis.

Humalog U-200 KwikPen is available as 3mL cartridges in 2-count packages.

For more information call (800) 545-5979 or visit Humalog.com.

You must be a registered member of Endocrinology Advisor to post a comment.

Sign Up for Free e-Newsletters



CME Focus